Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

With over 12 million Filipinos affected and billions lost to treatment costs, CKD remains one of the country’s most ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to ...

Sanofi is to take on Boehringer Ingelheim's consumer health division in exchange for its animal health business Merial – the latest in a trend for multi-billion swaps in big pharma. The deal ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.

Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US.

NORTHAMPTON, MA / ACCESS Newswire / June 16, 2025 / In remote communities in Argentina, access to quality healthcare is a challenge for many different reasons, including a strong reliance on paper ...

Analysts have recently evaluated Elanco Animal Health and provided 12-month price targets. The average target is $15.25, ...

What happens when data projects forget the people who use them? A Disconnect. Boehringer Ingelheim turned things around by ...

TOKYO -- German drugmaker Boehringer Ingelheim plans to invest a total of 300 million euros ($346 million) in its plant in Japan from 2023 to 2028 as it moves to make the facility a production base ...

Boehringer Ingelheim Pharma GmbH & Co KG has selected a third oncology drug candidate to advance into IND-enabling studies under its ongoing collaboration with Oxford Biotherapeutics Ltd.